Determination of voriconazole in saliva - Validation in specifif subsets of patients. - Determination of voriconazole in saliva

niversity Hospitals Leuven, Belgium0 个研究点目标入组 50 人开始时间: 2021年4月6日最近更新: 2021年4月26日

适应症

试验速览

暂无简介。

•Adult patients suffering from an invasive fungal infection, therefore treated with intravenous or oral voriconazole, admitted to the adult pneumology or hematology or internal medicine ward.
•Pediatric patients between 5-18 years suffering from an invasive fungal infection, treated with intravenous or oral voriconazole.
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 20
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•less than 5 years of age, women who are pregnant/lactating, patients suffering from severe mucositis (WHO grade 3 or 4), patients treated with drugs interacting with voriconazole (rifampicine, rifabutin, carbamazepine, phenytoin, phenobarbital, nevirapine, efavirenz, barbiturates, quinidine, ergotamine, sirolimus, saquinavir, amprenavir, nelfinavir, delvardine, ritonavir, sulphonylureas.

发起方

niversity Hospitals Leuven, Belgium